The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.
Sang Joon Shin
No relevant relationships to disclose
Jeeyun Lee
No relevant relationships to disclose
Ik-Joo Chung
No relevant relationships to disclose
Tae Won Kim
No relevant relationships to disclose
Hoo Geun Chun
No relevant relationships to disclose
Dongbok Shin
No relevant relationships to disclose
Yeul Hong Kim
No relevant relationships to disclose
Hong-Suk Song
No relevant relationships to disclose
Sae-Won Han
No relevant relationships to disclose
Jong Gwang Kim
No relevant relationships to disclose
Sun Young Kim
No relevant relationships to disclose
Young Jin Choi
No relevant relationships to disclose
Hyun Cheol Chung
No relevant relationships to disclose